• HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
Tuesday, November 17, 2026
BIOENGINEER.ORG
No Result
View All Result
  • Login
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
No Result
View All Result
Bioengineer.org
No Result
View All Result
Home NEWS Science News Biology

Retrospective Study Characterizes Hematologic Changes in Patients Receiving Docetaxel Chemotherapy

by
November 17, 2026
in Biology
Reading Time: 5 mins read
0
Retrospective Study Characterizes Hematologic Changes in Patients Receiving Docetaxel Chemotherapy

Retrospective Study Characterizes Hematologic Changes in Patients Receiving Docetaxel Chemotherapy

Share on FacebookShare on TwitterShare on LinkedinShare on RedditShare on Telegram

A retrospective observational study involving 67 adults with solid tumors has characterized hematologic changes and explored the relationship between candidate genetic variants and post-treatment blood count levels following docetaxel-containing chemotherapy. Conducted at an institution in Inner Mongolia, the study aimed to integrate paired laboratory measurements with descriptive assessment of cytopenia to provide a clearer understanding of the hematologic impacts observed during routine clinical care. The researchers found that while both white blood cell and absolute neutrophil counts significantly declined following the index chemotherapy cycle, none of the 16 evaluated candidate genetic variants showed associations that met the required thresholds for significance after accounting for multiple testing.

Docetaxel, a widely utilized semisynthetic taxane, functions by binding to beta-tubulin to stabilize microtubules, which effectively disrupts spindle dynamics and halts mitosis. This mechanism is central to its efficacy against a range of solid tumors, including breast, lung, gastric, ovarian, and prostate cancers. However, the use of docetaxel-containing regimens is frequently complicated by hematologic toxicities, particularly leukopenia and neutropenia. These adverse events are of significant clinical concern as they are linked to an increased risk of infectious complications, the necessity for hospitalization, potential treatment delays, and forced dose reductions, all of which may compromise the intensity of the intended therapy and overall treatment outcomes.

The study design focused on 67 eligible patients who received docetaxel at a dose of 70 mg/m2 as part of tumor-specific combination regimens between June 2021 and March 2022. Clinical information, laboratory measurements, and genetic data were retrospectively extracted from the institution’s medical records. To ensure the study captured clear comparative data, the researchers required each patient to have at least one pretreatment measurement and one post-treatment measurement taken between three and 10 days after an index chemotherapy cycle. Eligible participants were aged 18 or older, maintained a Karnofsky Performance Status score of at least 60, and had baseline clinical assessments compatible with chemotherapy protocols.

The researchers excluded patients with moderate or severe hepatic or renal dysfunction, those receiving concurrent medications identified as clinically relevant CYP3A inducers or inhibitors, or those who had undergone radiotherapy during the period of assessment. The treatment protocols followed local clinical practice, with the hierarchical classification of combination regimens into those containing fluoropyrimidines, those containing cyclophosphamides without fluoropyrimidines, and platinum-containing regimens. Other variables, such as G-CSF prophylaxis and therapeutic use, were also systematically recorded.

To evaluate hematologic toxicity, the study utilized a system of study-defined hematologic grades for WBC, ANC, hemoglobin, and platelet counts, categorized from 0 to 4. Grade 3 and 4 thresholds were specifically labeled as severe within this system. The researchers noted that these grades were based on selected post-treatment measurements and did not require an increase in severity relative to baseline, nor were they derived from systematically ascertained nadirs.

The findings showed substantial hematologic changes. Mean WBC counts dropped from a pretreatment baseline of 5.67 × 109/L to a post-treatment mean of 3.79 × 109/L, representing a mean change of −1.88 × 109/L. Similarly, the mean absolute neutrophil count decreased from 3.38 × 109/L to 2.22 × 109/L, a change of −1.16 × 109/L. Both changes reached statistical significance with unadjusted P values below 0.001 in paired t-test and Wilcoxon analyses. Regarding study-defined severe cytopenias at the selected assessment, 26.9% of records met the criteria for Grade 3–4 leukopenia, and 28.4% met the criteria for Grade 3–4 neutropenia. Grade 3–4 anemia was reported in 9.0% of the cohort, while no instances of Grade 3–4 thrombocytopenia were documented.

In the pharmacogenetic component of the study, the researchers analyzed 16 candidate variants across genes involved in docetaxel disposition, including CYP3A5, CYP1B1, CYP2D6, CYP39A1, ABCB1, ABCC2, ABCC6, ABCG2, SLCO1B3, and FMO2. The association analyses employed ordinary least squares regression, adjusting for baseline laboratory measurements and clinical covariates such as age, sex, body surface area, alanine aminotransferase levels, sampling day, index cycle, prophylactic G-CSF, and tumor type. Benjamini–Hochberg correction was applied to control the false discovery rate across 80 primary additive tests and 230 estimable alternative-model tests.

The results of these genetic explorations indicated that while four of the 80 primary additive tests showed unadjusted P values below 0.05, none of these reached the multiplicity-adjusted significance threshold of q < 0.05. The smallest q value observed was 0.666. Specifically, nominal associations involving ABCC2 rs12762549, ABCC2 rs2804402, and SLCO1B3 rs7311358 failed to withstand the rigorous adjustment for multiple testing. The study also evaluated CYP1B1 rs1056836 using alternative inheritance models. While adjusted post-treatment differences for WBC and ANC were observed under a dominant model comparing GC/GG with CC genotypes, these findings also did not meet the adjusted significance threshold, yielding q values of 0.882.

Sensitivity analyses conducted to test the robustness of these findings—including restricting sampling to days 7–10, excluding therapeutic G-CSF use, and employing natural-log transformations—consistently failed to identify associations that achieved the target adjusted significance levels. The confidence intervals for the adjusted differences and ratios of geometric means generally included the null value in these supplementary checks. These results suggest that the variations evaluated in this specific candidate-gene set do not, in this cohort, demonstrate clear, statistically supported links to the observed hematologic outcomes when correcting for the multiplicity of the tests performed.

The researchers noted that these findings contrast with some previous studies that reported associations between certain variants, such as ABCC2 rs12762549 and SLCO1B3 rs11045585, and severe toxicity. They suggested that differences in study methodology likely contribute to these discrepancies, including variations in defining cytopenia, the timing of blood sampling, the statistical approaches to multiple testing, and the specific patient populations studied. The current study focused on continuous post-treatment counts adjusted for baseline, whereas other literature often examines categorical toxicity outcomes or longitudinal count ratios. Furthermore, the limited sample size and sparse genotype groups inherent in this retrospective cohort may impact the stability of the association estimates.

Limitations identified by the authors include the retrospective nature of the study, the relatively small sample size, and the reliance on a single-center dataset, which restricts the generalizability of the findings. The absence of systematically ascertained nadirs and the variability in post-treatment sampling times limit the ability to draw conclusions regarding maximum hematologic severity or to fully compare these findings with standardized toxicity reporting criteria. Additionally, the analysis did not account for specific companion-drug doses, total cumulative drug exposure, or comprehensive records of all concomitant medications, leaving potential for residual confounding.

Ultimately, the researchers concluded that while mean WBC and ANC levels were demonstrably lower following docetaxel-based treatment, the evaluated candidate genetic variants did not demonstrate associations that would support their current clinical use in genotype-guided docetaxel dosing or prophylactic strategies. The team emphasized that laboratory cytopenia and clinically consequential events like febrile neutropenia remain distinct, and further research is necessary to identify predictive factors that possess genuine clinical utility in oncology supportive care.

Subject of Research: Retrospective evaluation of hematologic changes and pharmacogenetic associations in patients treated with docetaxel-containing chemotherapy.

Article Title: Hematologic outcomes and exploratory pharmacogenetic associations in patients receiving docetaxel-containing chemotherapy: a retrospective study

Article References: Tian, X.-M., Lu, L.-S., Yao, Y.-C., Wang, Y., Xie, P.-T., He, R.-P., Wang, D., & Yang, Q. (2026). Hematologic outcomes and exploratory pharmacogenetic associations in patients receiving docetaxel-containing chemotherapy: a retrospective study. Frontiers in Genetics, 17, Article 1996630. https://doi.org/10.3389/fgene.2026.1996630

Image Credits: AI Generated

DOI: 10.3389/fgene.2026.1996630

Keywords: Docetaxel, chemotherapy, hematologic toxicity, neutropenia, leukopenia, pharmacogenetics, retrospective study, solid tumors, white blood cell count, clinical outcomes, candidate-gene analysis, CYP1B1, ABCC2, patient safety, oncology research, genomic medicine

News Source: Nathaniel Bowman. (November 17, 2026). Retrospective Study Characterizes Hematologic Changes in Patients Receiving Docetaxel Chemotherapy. Scienmag.

Tags: ABCC2candidate-gene analysischemotherapyclinical outcomesCYP1B1docetaxelgenomic medicinehematologic toxicityleukopenianeutropeniaoncology researchPatient SafetyPharmacogeneticsRetrospective studysolid tumorswhite blood cell count
Share12Tweet7Share2ShareShareShare1

Related Posts

CT Findings Prompted Empirical Albendazole Treatment Despite Negative Stool Microscopy in Patient

CT Findings Prompted Empirical Albendazole Treatment Despite Negative Stool Microscopy in Patient

November 17, 2026
Review Finds African Ethnobiological Knowledge Has Measurable Conservation Value

Review Finds African Ethnobiological Knowledge Has Measurable Conservation Value

November 17, 2026

Medaka Genomes Reveal Divergent Sex-Determining Chromosomes in DMY-Deficient Lineages

November 17, 2026

MAGOH Axis Generates Soluble PD-L1 Decoys Impairing Gastric Cancer Immunotherapy

November 17, 2026

POPULAR NEWS

  • Alloplastic Temporomandibular Joint Replacement Offers Uncertain Benefits After Mandibular Neoplasm Resection

    Alloplastic Temporomandibular Joint Replacement Offers Uncertain Benefits After Mandibular Neoplasm Resection

    29 shares
    Share 12 Tweet 7
  • Serum Mass Spectrometry Predicts Treatment Response in HER2-Positive Breast Cancer

    29 shares
    Share 12 Tweet 7
  • Polypharmacy Linked to Higher Odds of Sarcopenia in Older Adults

    29 shares
    Share 12 Tweet 7
  • Adapted Virtual Presence Tool Proves Feasible in Pilot Manikin Simulation Courses

    29 shares
    Share 12 Tweet 7

About

We bring you the latest biotechnology news from best research centers and universities around the world. Check our website.

Follow us

Recent News

Extremely Rare Glycogen Storage Disease Type VI Diagnosed Amidst Celiac Disease

Futibatinib Bridges Blast-Phase MLN-FGFR1 to Allogeneic Transplantation in Clinical Report

Seventeenth century pirate codes established early collective models for injury compensation

Subscribe to Blog via Email

Enter your email address to subscribe to this blog and receive notifications of new posts by email.

Join 88 other subscribers
  • Contact Us

Bioengineer.org © Copyright 2023 All Rights Reserved.

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In
No Result
View All Result
  • Homepages
    • Home Page 1
    • Home Page 2
  • News
  • National
  • Business
  • Health
  • Lifestyle
  • Science

Bioengineer.org © Copyright 2023 All Rights Reserved.